(Q44841298)

6 December 2017

Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

Graham Scott

1

1 reference

6 December 2017

Christine Vinluan Reynolds

2

1 reference

6 December 2017

Slavica Milosavljev

3

1 reference

6 December 2017

Wayne Langholff

4

1 reference

6 December 2017

Magdy Shenouda

5

1 reference

6 December 2017

Christiane Rordorf

6

1 reference

6 December 2017

1 January 2004

1 reference

6 December 2017

8

1 reference

Clinical Pharmacokinetics

inferred from page(s)

published in

1 reference

6 December 2017

43

1 reference

6 December 2017

5

1 reference

6 December 2017

341-348

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200443050-00006

6 December 2017

0 references

cites work

Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be useless

1 reference

12 December 2020

Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.

1 reference

12 December 2020

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

1 reference

12 December 2020

The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac

1 reference

12 December 2020

Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids

1 reference

12 December 2020

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

1 reference

12 December 2020

Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders

1 reference

12 December 2020

Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole

1 reference

12 December 2020

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study

1 reference

12 December 2020

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

12 December 2020

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

12 December 2020

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

1 reference

12 December 2020

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

1 reference

12 December 2020

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole

1 reference

12 December 2020

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

12 December 2020

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

1 reference

12 December 2020

10.2165/00003088-200443050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

6 December 2017

0 references

1 reference